menu
    • menu
    [{"orgOrder":0,"company":"Ipsen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ipsen Finds Over 80% Of Patients with Spasticity And Cervical Dystonia Treated With Botulinum Toxin-A Experience Symptom Recurrence","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase IV","country":"","productType":"Large molecule","productStatus":"Approved","date":"May 2020","year":"2020","type":"Not Applicable","leadProduct":"Botulinum toxin type A","moa":"SNAP-25","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Ipsen","amount2":0,"therapeuticAreaNew":"Musculoskeletal","highestDevelopmentStatusNew":"Phase IV","highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","productSubType":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Ipsen \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Ipsen \/ No.."}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Horizon Therapeutics

                            Ireland arrow
                            BioProcess International
                            Not Confirmed

                            Horizon Therapeutics

                            Ireland arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegloticase,Methotrexate

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Results from PROTECT Trial Evaluating KRYSTEXXA® (Pegloticase Injection) in Kidney Transplant Rec...

                            Details : The results from the completed PROTECT trial (NCT04087720) demonstrated that Krystexxa (Pegloticase & Methotrexate) provide a substantial and sustained decrease in serum uric acid (sUA) for patients with ...

                            Brand Name : Krystexxa

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 04, 2021

                            Lead Product(s) : Pegloticase,Methotrexate

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Horizon Therapeutics

                            Ireland arrow
                            BioProcess International
                            Not Confirmed

                            Horizon Therapeutics

                            Ireland arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegloticase,Methotrexate

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New Data Being Presented at American College of Rheumatology Convergence 2021 Highlight Horizon’...

                            Details : The findings indicated that the use of KRYSTEXXA with an immunomodulator may improve persistence to therapy. Approx 90% of the evaluated population met the sUA treatment target and those who received immu...

                            Brand Name : Krystexxa

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 01, 2021

                            Lead Product(s) : Pegloticase,Methotrexate

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Horizon Therapeutics

                            Ireland arrow
                            BioProcess International
                            Not Confirmed

                            Horizon Therapeutics

                            Ireland arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegloticase,Methotrexate

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            MIRROR Randomized Controlled Trial Meets Primary Endpoint and Shows 71% of Patients Achieved a Com...

                            Details : Results show that 71% (71 of 100) of patients who were randomized to receive KRYSTEXXA with methotrexate compared to 40% (21 of 52) of patients who were randomized to receive KRYSTEXXA with placebo achiev...

                            Brand Name : Krystexxa

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 25, 2021

                            Lead Product(s) : Pegloticase,Methotrexate

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Horizon Therapeutics

                            Ireland arrow
                            BioProcess International
                            Not Confirmed

                            Horizon Therapeutics

                            Ireland arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegloticase,Methotrexate

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase IV

                            Sponsor : University of Michigan

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Data Published in Arthritis & Rheumatology Show Higher Response Rates of Horizon's KRYSTEXXA with ...

                            Details : The Reducing Immunogenicity of Pegloticase trial showed that 86% of patients receiving co-therapy of KRYSTEXXA with the immunomodulator mycophenolate mofetil achieved serum uric acid (sUA) ≤ 6 mg/dL at ...

                            Brand Name : Krystexxa

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 07, 2021

                            Lead Product(s) : Pegloticase,Methotrexate

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase IV

                            Sponsor : University of Michigan

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Horizon Therapeutics

                            Ireland arrow
                            BioProcess International
                            Not Confirmed

                            Horizon Therapeutics

                            Ireland arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegloticase,Methotrexate

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First Patient Enrolls in Horizon's FORWARD Trial to Evaluate Monthly Dosing of KRYSTEXXA and Metho...

                            Details : The current recommended dosing of KRYSTEXXA for adult patients is 8 mg given as intravenous infusions every two weeks, with each dose infused over at least two hours.

                            Brand Name : Krystexxa

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 25, 2021

                            Lead Product(s) : Pegloticase,Methotrexate

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Horizon Therapeutics

                            Ireland arrow
                            BioProcess International
                            Not Confirmed

                            Horizon Therapeutics

                            Ireland arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegloticase,Methotrexate

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Horizon Therapeutics Provides Update on TEPEZZA® (teprotumumab-trbw) Supply and New KRYSTEXXA® (...

                            Details : The Company announced two new KRYSTEXXA development programs: KRYSTEXXA, with methotrexate monthly dosing trial and a KRYSTEXXA retreatment trial evaluating KRYSTEXXA, with methotrexate, in patients who h...

                            Brand Name : Krystexxa

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 11, 2021

                            Lead Product(s) : Pegloticase,Methotrexate

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Horizon Therapeutics

                            Ireland arrow
                            BioProcess International
                            Not Confirmed

                            Horizon Therapeutics

                            Ireland arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pegloticase

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New Data Offers Insights on Treatment with KRYSTEXXA® Among Kidney Transplant Patients for the Ma...

                            Details : The real-world usage analysis illustrates that KRYSTEXXA is effectively employed and well-tolerated among dialysis patients. KRYSTEXXA® is a PEGylated uric acid specific enzyme indicated for the treatmen...

                            Brand Name : Krystexxa

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 22, 2020

                            Lead Product(s) : Pegloticase

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable